Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has been assigned an average recommendation of “Hold” from the twenty-two analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $13.84.

ENDP has been the topic of a number of recent research reports. Citigroup raised shares of Endo International from a “neutral” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Wednesday, June 27th. Mizuho lifted their price target on shares of Endo International to $17.00 and gave the company a “neutral” rating in a research report on Tuesday. Canaccord Genuity set a $7.00 price target on shares of Endo International and gave the company a “hold” rating in a research report on Tuesday, May 8th. BidaskClub raised shares of Endo International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 16th. Finally, B. Riley lifted their price target on shares of Endo International from $10.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, June 28th.

ENDP stock traded down $0.31 during midday trading on Friday, reaching $15.64. 4,678,415 shares of the company’s stock traded hands, compared to its average volume of 6,003,341. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of 4.07, a price-to-earnings-growth ratio of 3.01 and a beta of 0.49. The company has a quick ratio of 0.91, a current ratio of 1.07 and a debt-to-equity ratio of -132.64. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $17.34.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.22. The firm had revenue of $714.70 million for the quarter, compared to analysts’ expectations of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. Endo International’s revenue was down 18.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.93 earnings per share. equities analysts forecast that Endo International will post 2.6 EPS for the current fiscal year.

In other news, Director Roger H. Kimmel sold 26,074 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Xact Kapitalforvaltning AB lifted its position in shares of Endo International by 22.2% during the second quarter. Xact Kapitalforvaltning AB now owns 35,715 shares of the company’s stock worth $337,000 after purchasing an additional 6,500 shares in the last quarter. Diamond Hill Capital Management Inc. increased its stake in shares of Endo International by 1.0% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after buying an additional 10,600 shares during the last quarter. Neuburgh Advisers LLC increased its stake in shares of Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after buying an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC increased its stake in shares of Endo International by 83.9% in the first quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock worth $245,000 after buying an additional 18,800 shares during the last quarter. Finally, Tyers Asset Management LLC increased its stake in shares of Endo International by 84.2% in the first quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock worth $274,000 after buying an additional 21,084 shares during the last quarter. 95.89% of the stock is currently owned by institutional investors and hedge funds.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.